Betensky RA - Search Results

1

Histology-based expression profiling yields novel prognostic markers in human glioblastoma.

Dong S, Nutt CL, Betensky RA, Stemmer-Rachamimov AO, Denko NC, Ligon KL, Rowitch DH, Louis DN. Dong S, et al. Among authors: betensky ra. J Neuropathol Exp Neurol. 2005 Nov;64(11):948-55. doi: 10.1097/01.jnen.0000186940.14779.90. J Neuropathol Exp Neurol. 2005. PMID: 16254489 Free PMC article.

2

Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis.

Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, Ramsay DA, Cairncross JG, Louis DN. Ino Y, et al. Among authors: betensky ra. Clin Cancer Res. 2001 Apr;7(4):839-45. Clin Cancer Res. 2001. PMID: 11309331

3

PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis.

Sasaki H, Zlatescu MC, Betensky RA, Ino Y, Cairncross JG, Louis DN. Sasaki H, et al. Among authors: betensky ra. Am J Pathol. 2001 Jul;159(1):359-67. doi: 10.1016/S0002-9440(10)61702-6. Am J Pathol. 2001. PMID: 11438483 Free PMC article.

4

Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms.

Zlatescu MC, TehraniYazdi A, Sasaki H, Megyesi JF, Betensky RA, Louis DN, Cairncross JG. Zlatescu MC, et al. Among authors: betensky ra. Cancer Res. 2001 Sep 15;61(18):6713-5. Cancer Res. 2001. PMID: 11559541

5

Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma".

Sasaki H, Zlatescu MC, Betensky RA, Johnk LB, Cutone AN, Cairncross JG, Louis DN. Sasaki H, et al. Among authors: betensky ra. J Neuropathol Exp Neurol. 2002 Jan;61(1):58-63. doi: 10.1093/jnen/61.1.58. J Neuropathol Exp Neurol. 2002. PMID: 11829344

6

The use of frailty hazard models for unrecognized heterogeneity that interacts with treatment: considerations of efficiency and power.

Li Y, Betensky RA, Louis DN, Cairncross JG. Li Y, et al. Among authors: betensky ra. Biometrics. 2002 Mar;58(1):232-6. doi: 10.1111/j.0006-341x.2002.00232.x. Biometrics. 2002. PMID: 11890320

7

DMBT1 polymorphisms: relationship to malignant glioma tumorigenesis.

Sasaki H, Betensky RA, Cairncross JG, Louis DN. Sasaki H, et al. Among authors: betensky ra. Cancer Res. 2002 Mar 15;62(6):1790-6. Cancer Res. 2002. PMID: 11912156

8

Influence of unrecognized molecular heterogeneity on randomized clinical trials.

Betensky RA, Louis DN, Cairncross JG. Betensky RA, et al. J Clin Oncol. 2002 May 15;20(10):2495-9. doi: 10.1200/JCO.2002.06.140. J Clin Oncol. 2002. PMID: 12011127

9

BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma.

Braaten KM, Betensky RA, de Leval L, Okada Y, Hochberg FH, Louis DN, Harris NL, Batchelor TT. Braaten KM, et al. Among authors: betensky ra. Clin Cancer Res. 2003 Mar;9(3):1063-9. Clin Cancer Res. 2003. PMID: 12631608

10

Gene expression-based classification of malignant gliomas correlates better with survival than histological classification.

Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, Ladd C, Pohl U, Hartmann C, McLaughlin ME, Batchelor TT, Black PM, von Deimling A, Pomeroy SL, Golub TR, Louis DN. Nutt CL, et al. Among authors: betensky ra. Cancer Res. 2003 Apr 1;63(7):1602-7. Cancer Res. 2003. PMID: 12670911

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

290 results

Search Page

Filters